Body fluid biomarkers for early detection of head and neck squamous cell carcinomas

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1161-1167

  Lee, Kang Dae ^a   Lee, Hyoung Shin ^a   Jeon, Chang Ho ^b  

^a Kosin University   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

Biomarkers; Diagnosis; Early detection; Head and neck cancer; Review

Indexed keywords

ACTIN; CYTOKERATIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MELANOMA ANTIGEN; MICRORNA; MYOSIN; TUMOR MARKER;

BODY FLUID; CANCER DIAGNOSIS; CANCER STAGING; EARLY DIAGNOSIS; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROTEIN METHYLATION; REVIEW; SALIVARY GLAND; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

BODY FLUIDS; CARCINOMA, SQUAMOUS CELL; EARLY DIAGNOSIS; HEAD AND NECK NEOPLASMS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956127269     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Boyle P and Levin B: World Cancer Report 2008. International Agency for Research on Cancer. Lyon, France p. 330, 2008.
3. Annertz K, Anderson H, Biorklund A, Moller T, Kantola S, Mork J, Olsen JH and Wennerberg J: Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer 101: 95-99, 2002. (Pubitemid 34833003)
4. Rossini AR, Hashimoto CL, Iriya K, Zerbini C, Baba ER and Moraes-Filho JP: Dietary habits, ethanol and tobacco consumption as predictive factors in the development of esophageal carcinoma in patients with head and neck neoplasms. Dis Esophagus 21: 316-321, 2008.
5. Tran N, Rose BR and O'Brien CJ: Role of human papillomavirus in the etiology of head and neck cancer. Head Neck 29: 64-70, 2007. (Pubitemid 46032569)
6. Mashberg A and Samit A: Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. CA Cancer J Clin 45: 328-351, 1995.
7. Mydlarz WK, Hennessey PT and Califano JA: Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin Med Diag 4: 53-65, 2010.
8. Schaaij-Visser T, Brakenhoff RH, Leemans CR, Heck AJR and Slijper M: Protein biomarker discovery for head and neck cancer. J Proteomics 73: 1790-1803, 2010.
9. Lam L, Logan RM, Luke C and Rees GL: Retrospective study of survival and treatment pattern in a cohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004. Oral Oncol 43: 150-158, 2007.
10. Tran N, O'Brien CJ, Clark J and Rose B: Potential role of micro-RNAs in head and neck tumorigenesis. Head Neck 32: 1099-1111, 2010.
11. Rodrigo JP, Ferlito A, Suarez C, Shaha AR, Silver CE, Devaney KO, Bradley PJ, Bocker JM, McLaren KM, Grenman R and Rinaldo A: New molecular diagnostic methods in head and neck cancer. Head Neck 27: 995-1003, 2005. (Pubitemid 41552146)
12. Sidransky D, Irizarry R, Califano JA, Li X, Ren H, Benoit N and Mao L: Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects. J Natl Cancer Inst 95: 1711-1717, 2003. (Pubitemid 37521219)
13. Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park NH and Wong DT: Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 10: 8442-8450, 2004. (Pubitemid 40053408)
14. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA and Wong DT: Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 14: 6246-6252, 2008.
15. St. John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R, Wolinsky L, Park NH, Liu H, Abemayor E and Wong DT: Interleukin-6 and interleukin-8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 130: 929-935, 2004. (Pubitemid 39045599)
16. Park NJ, Zhou X, Yu T, Brinkman BM, Zimmermann BG, Palanisamy V and Wong DT: Characterization of salivary RNA by cDNA library analysis. Arch Oral Biol 52: 30-35, 2007. (Pubitemid 44853926)
17. Hurteau GJ and Spivack SD: mRNA-specific reverse transcription-polymerase chain reaction from human tissue extracts. Anal Biochem 307: 304-315, 2002. (Pubitemid 35026205)
18. Zimmermann BG, Park NJ and Wong DT: Genomic targets in saliva. Ann N Y Acad Sci 1098: 184-191, 2007.
19. Mahfouz ME, Rodrigo JP, Takes RP, Elsheikh MN, Rinaldo A, Brakenhoff RH and Ferlito A: Current potential and limitations of molecular diagnostic methods in head and neck cancer. Eur Arch Otorhinolaryngol 267: 851-860, 2010.
20. Nunes DN, Kowalski LP and Simpson AJ: Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings. Oral Oncol 36: 525-528, 2000.
21. Blons H, Cabelguenne A, Carnot F, Laccourreye O, de Waziers I, Hamelin R, Brasnu D, Beaune P and Laurent-Puig P: Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int J Cancer 84: 410-415, 1999. (Pubitemid 29337129)
22. Lin SC, Chang MF, Chung MY, Chang CS, Kao SY, Liu CJ and Chang KW: Frequent microsatellite alterations of chromosome locus 4q13.1 in oral squamous cell carcinomas. J Oral Pathol Med 34: 209-213, 2005.
23. Yalniz Z, Demokan S, Suoglu Y, Ulusan M and Dalay N: Assessment of microsatellite instability in head and neck cancer using consensus markers. Mol Biol Rep 37: 3541-3545, 2010.
24. Maehara Y, Oda S and Sugimachi K: The instability within: Problems in current analyses of microsatellite instability. Mutat Res 461: 249-263, 2001.
25. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG and Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60: 892-895, 2000. (Pubitemid 30129522)
26. 6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61: 939-942, 2001.
27. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon Cs, Koch W, Westra WH, Sidransky D and Califano JA: Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 14: 97-107, 2008. (Pubitemid 351377983)
28. Jang SJ, Soria JC, Wang L, Hassan KA, Morice RC, Walsh GL, Hong WK and Mao L: Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 61: 7959-7963, 2001. (Pubitemid 33049388)
29. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL and Yuen AP: The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 39: 1881-1887, 2003.
30. Chang HW, Ling GS, Wei WI and Yuen AP: Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. Cancer 101: 125-132, 2004. (Pubitemid 38812431)
31. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA and Crowell RE: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377, 2002. (Pubitemid 34411720)
32. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000. (Pubitemid 30123793)
33. Ravanti L and Kahari VM: Matrix metalloproteinases in wound repair (review). Int J Mol Med 6: 391-407, 2000.
34. Duffy MJ and McCarthy K: Matrix metalloproteinases in cancer: Prognostic markers and targets for therapy (review). Int J Oncol 12: 1343-1348, 1998. (Pubitemid 28239947)
35. Marcos CA, Martinez DAK, de los Toyos JR, Domínguez Iglesias F, Hermsen M, Guervós MA and Pendás JLL: The usefulness of new serum tumor markers in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 140: 375-380, 2009.
36. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A and Ferris RL: Early detection of head and neck cancer: Development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomark Prev 16: 102-107, 2007. (Pubitemid 46174271)
37. Zucker S, Lysik RM, Zarrabi MH and Moll U: M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146, 1993.
38. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson WG and Liotta LA: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52: 4548-4549, 1992.
39. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Romanini C and Biagini G: Increased serum 72 kDa metalloproteinase in serous ovarian tumors: Comparison with CA 125. Anticancer Res 16: 2123-2127, 1996. (Pubitemid 26270736)
40. Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H and Werner JA: Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res 22: 2221-2227, 2002.
41. Yen CY, Chen CH, Chang CH, Tseng HF, Liu SY, Chuang LY, Wen CH and Chang HW: Matrix metalloproteinases (MMP)-1 and MMP-10 but not MMP-12 are potential oral cancer markers. Biomarkers 14: 244-249, 2009.
42. Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffe E and Ines Puricelli L: Circulating 92-kiloDalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 94: 1483-1491, 2002. (Pubitemid 34212642)
43. Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M, Lastiri J, Pallotta MG, Bal de Kier Joffe E and Puricelli L: Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 89: 389-394, 2000. (Pubitemid 30620294)
44. Kato Y, Nakayama Y, Umeda M and Miyazaki K: Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 267: 11424-11430, 1992.
45. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J and Somiari RI: Plasma concentration and activity of matrix metalloproteinase-2 and -9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 233: 98-107, 2006. (Pubitemid 43214567)
46. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL and Van Waes C: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379, 1999. (Pubitemid 29282941)
47. SahebJamee M, Eslami M, AtarbashiMoghadam F and Sarafnejad A: Salivary concentration of TNFalpha, IL-1 alpha, IL-6, and IL-8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 13: E292-295, 2008.
48. Toyoshima T, Vairaktaris E, Nkenke E, Schlegel KA, Neukam FW and Ries J: Cytokeratin-17 mRNA expression has potential for diagnostic marker of oral squamous cell carcinoma. J Cancer Res Clin Oncol 134: 515-521, 2008.
49. Troyanovsky SM, Guelstein VI, Tchipysheva TA, Krutovskikh VA and Bannikov GA: Patterns of expression of keratin-17 in human epithelia: Dependency on cell position. J Cell Sci 93: 419-426, 1989. (Pubitemid 19188086)
50. Domachowske JB, Bonville CA and Rosenberg HF: Cytokeratin-17 is expressed in cells infected with respiratory syncytial virus via NF-kappa B activation and is associated with the formation of cytopathic syncytia. J Infect Dis 182: 1022-1028, 2000.
51. Cohen-Kerem R, Madah W, Sabo E, Rahat MA, Greenberg E and Elmalah I: Cytokeratin-17 as a potential marker for squamous cell carcinoma of the larynx. Ann Otol Rhinol Laryngol 113: 821-827, 2004. (Pubitemid 39362228)
52. Toyoshima T, Koch F, Kaemmerer P, Vairaktaris E, Al-Nawas B and Wagner W: Expression of cytokeratin-17 mRNA in oral squamous cell carcinoma cells obtained by brush biopsy: Preliminary results. J Oral Pathol Med 38: 530-534, 2009.
53. Wei KJ, Zhang L, Yang X, Zhong LP, Zhou XJ, Pan HY, Li J, Chen WT and Zhang ZY: Overexpression of cytokeratin-17 protein in oral squamous cell carcinoma in vitro and in vivo. Oral Dis 15: 111-117, 2009.
54. Ke XS, Liu CM, Liu DP and Liang CC: MicroRNAs: key participants in gene regulatory networks. Curr Opin Chem Biol 4: 516-23, 2003
55. Kent OA and Mendell JT: A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196, 2006. (Pubitemid 44527849)
56. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
57. Jiang J, Lee EJ, Gusev Y and Schmittgen TD: Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33: 5394-5403, 2005. (Pubitemid 41548806)
58. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E and Wong DT: Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 75: 5473-5477, 2009.
59. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O'Sullivan B, Waldron J, Gullane P, Cummings B and Liu FF: Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16: 1129-1139, 2010.
60. de Jong EP, Xie H, Onsongo G, Stone MD, Chen XB, Kooren JA, Refsland EW, Griffin RJ, Ondrey FG, Wu B, Le CT, Rhodus NL, Carlis JV and Griffin TJ: Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing premalignant and malignant oral lesions. PLoS One 5: e11148, 2010.
61. Friedl P and Gilmour D: Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 10: 445-457, 2009.
62. Olson MF and Sahai E: The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 26: 273-287, 2009.
63. Alt-Holland A, Shamis Y, Riley KN, DesRochers TM, Fusenig NE, Herman IM and Garlick JA: E-Cadherin suppression directs cytoskeletal rearrangement and intraepithelial tumor cell migration in 3D human skin equivalents. J Invest Dermatol 128: 2498-2507, 2008.
64. Uzquiano MC, Prieto VG, Nash JW, Ivan DS, Gong Y, Lazar AJ and Diwan AH: Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol 21: 540-543, 2008. (Pubitemid 351589650)
65. Li Q, Huang W and Zhou X: Expression of CD34, alpha-smooth muscle actin and transforming growth factor-beta1 in squamous intraepithelial lesions and squamous cell carcinoma of the cervix. J Int Med Res 37: 446-454, 2009.
66. Qi Y, Chiu JF, Wang L, Kwong DL and He QY: Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 5: 2960-2971, 2005. (Pubitemid 41059772)
67. Shi L, Sun SZ and Wang ZG: Expression of stromal CD34 and alpha-smooth muscle actin in oral invasive cancer. Zhonghua Kou Qiang Yi Xue Za Zhi 41: 106-107, 2006 (in Chinese).
68. Lo WY, Tsai MH, Tsai Y, Hua CH, Tsai FJ, Huang SY, Tsai CH and Lai CC: Identification of overexpressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 376: 101-107, 2007. (Pubitemid 44880973)
69. Turhani D, Krapfenbauer K, Thurnher D, Langen H and Fountoulakis M: Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 27: 1417-1423, 2006.
70. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, Peng H, Ivanov AV, Simpson AJ and Longley BJ: MAGE-A, mMAGE-B, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67: 9954-9962, 2007.
71. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991. (Pubitemid 21917508)
72. Van den Eynde BJ and van der Bruggen P: T-Cell-defined tumor antigens. Curr Opin Immunol 9: 684-693, 1997.
73. Kirkin AF, Dzhandzhugazyan K and Zeuthen J: Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS 106: 665-679, 1998. (Pubitemid 28383441)
74. Kienstra MA, Neel HB, Strome SE and Roche P: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25: 457-463, 2003.
75. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC and Resnick MB: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 9: 6453-6460, 2003. (Pubitemid 38031833)
76. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, Remmel E, Noppen C, Schmid U, Ackermann D, Mihatsch MJ, Gasser T, Heberer M, Sauter G and Spagnoli GC: Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study. Int J Cancer 700: 702-705, 2002. (Pubitemid 34832982)
77. Jheon S, Hyun DS, Lee SC,Yoon GS, Jeon CH, Park JW, Park CK, Jung MH, Lee KD and Chang HK: Lung cancer detection by a RT-nested PCR using MAGE A1-6 common primers. Lung Cancer 43: 29-37, 2004. (Pubitemid 38096289)
78. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y and Gu J: Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 11: 1809-1814, 2005.
79. Muller-Richter UD, Dowejko A, Reuther T, Kleinheinz J, Reichert TE and Driemel O: Analysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines. Head Face Med 5: 10, 2009.
80. Ries J, Vairaktaris E, Mollaoglu N, Wiltfang J, Neukam FW and Nkenke E: Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol Med 37: 88-93, 2008.
81. Lee KD, Lee CS, Lee HH, Lee YS, Chang HK, Jeon CH and Park JW: Experimental studies on the significance of new MAGE common primers detecting MAGE 1-6 mRNA in head and neck cancers. Korean J Otolaryngol 44: 736-743, 2001.
82. Metzler P, Mollaoglu N, Schwarz S, Neukam FW, Nkenke E and Ries J: MAGE-A as a novel approach in the diagnostic accuracy of oral squamous cell cancer: A case report. Head Neck Oncol 1: 39-45, 2009.
83. Lee KD, Lee HH, Joo HB, Ue HS, Yu TH, Chang HK, Jeon CH and Park JW: Expression of MAGE A 1-6 mRNA in sputa of head and neck cancer patients-a preliminary report. Anticancer Res 26: 1513-1518, 2006.
84. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC and Old LJ: Expression of MAGE antigens in normal tissues and cancer. Int J Cancer 85: 460-465, 2000. (Pubitemid 30075121)
85. Ries J, Schultze-Mosgau S, Neukam F, Diebel E and Wiltfang J: Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol 26: 817-824, 2005.
86. Pastorcic-Grgic M, Sarcevic B, Dosen D, Juretic A, Spagnoli GC and Grgic M: Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head Neck 32: 1178-1184, 2010.